You are here

  • Home
  • Archive
  • Volume 50, Issue suppl 4
  • Combined analysis of the ORCHID and OCAY studies: does eradication of Helicobacter pylori lead to sustained improvement in functional dyspepsia symptoms?

Article Text

Article menu
Download PDFPDF
Papers
Combined analysis of the ORCHID and OCAY studies: does eradication of Helicobacter pylori lead to sustained improvement in functional dyspepsia symptoms?
  1. S J O Veldhuyzen van Zanten1,
  2. N J Talley2,
  3. A L Blum3,
  4. E Bolling-Sternevald4,
  5. M Sundin5,
  6. O Junghard5
  1. 1Division of Gastroenterology, Dalhousie University, Halifax, Nova Scotia, Canada
  2. 2Department of Medicine, University of Sydney, Nepean Hospital, Penrith, Australia
  3. 3Division of Gastroenterology, Department of Medicine, University Hospital, Lausanne, Switzerland
  4. 4Department of Biomedicine and Surgery, University Hospital, Linköping, Sweden
  5. 5AstraZeneca R&D, Mölndal, Sweden
  1. Correspondence to:
    Dr S J O Veldhuyzen van Zanten, Division of Gastroenterology, Dalhousie University, Queen Elizabeth II Health Science Centre, Victoria General Site, Room 928, Centennial Building, Halifax, Nova Scotia, Canada B3H 2YG;
    zanten{at}is.dal.ca

Abstract

Currently, one of the most important unresolved questions concerning Helicobacter pylori is whether eradication of the organism leads to a sustained improvement in symptoms in patients diagnosed with functional (non-ulcer) dyspepsia. Recently, two very similar studies, the ORCHID and OCAY studies, have been completed and the combined results of these two multicentre, multinational, randomised, double blind, controlled clinical trials are reviewed.

  • clinical trial
  • dyspepsia
  • Helicobacter pylori
  • OCAY study
  • ORCHID study
  • quality of life
  • symptom relief
  • GDSS, Glasgow dyspepsia severity score
  • GORD, gastro-oesophageal reflux disease
  • GSRS, gastrointestinal symptom rating scale
  • ITT, intention to treat
  • MRC, Medical Research Council
  • OAC, omeprazole 20 mg twice daily, amoxycillin 1000 mg twice daily, and clarithromycin 500 mg twice daily for seven days
  • PGWB, psychological general well being

https://doi.org/10.1136/gut.50.suppl_4.iv26

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Conflict of interest: This symposium was sponsored by AstraZeneca, makers of omeprazole. The authors of this paper have received sponsorship for travel and an honorarium from AstraZeneca. NJ Talley has been a consultant and received research grants from TAP, Takeda, Ledede, Pharmacia, and Janssens.